Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Axcella Health (AXLA – Research Report) today and set a price target of $1.50. The company’s shares closed yesterday at $0.50.
LeBoyer covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, Axcella Health, and Onconova Therapeutics. According to TipRanks, LeBoyer has an average return of -3.5% and a 27.44% success rate on recommended stocks.
Currently, the analyst consensus on Axcella Health is a Moderate Buy with an average price target of $1.50.
See the top stocks recommended by analysts >>
Based on Axcella Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $17.84 million. In comparison, last year the company had a GAAP net loss of $15.61 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.
Read More on AXLA:
